Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express ...

Twist Bioscience Corporation, ... today announced the expansion of its DNA synthesis offering with the launch of Gene Fragments with increased lengths ranging from 1.8 kb to 5.0 kb.

Twist Bioscience and Ginkgo Bioworks Revise Collaboration. ... Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers.

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Guggenheim initiates coverage of Twist Bioscience (TWST) with a buy rating, citing its proprietary DNA synthesis platform and strong growth potential. Read more here.

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Twist Bioscience Spins Out DNA Data Storage as Independent Company. ... Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, ...

Twist Bioscience is offering 5,000,000 shares at $14 to $16 via JP Morgan and Cowen. At the midpoint of the filing range, it would be a $75 million transaction with a post-IPO market ...

“DNA synthesis is a core technology for synthetic biology and we’re happy to combine some of our long DNA technology with Twist to hopefully see more and varied ... At Twist Bioscience, ...